The Tuberculosis Drug Accelerator at year 10: what have we learned?

Bree B. Aldridge, David Barros-Aguirre, Clifton E. Barry, Robert H. Bates, Steven J. Berthel, Helena I. Boshoff, Kelly Chibale, Xin-Jie Chu, Christopher B. Cooper, Véronique Dartois, Ken Duncan, Nader Fotouhi, Fabian Gusovsky, Philip A. Hipskind, Dale J. Kempf, Joël Lelièvre, Anne J. Lenaerts, Case W. McNamara, Valerie Mizrahi, Carl Nathan (Lead / Corresponding author)David B. Olsen, Tanya Parish, H. Michael Petrassi, Alexander Pym, Kyu Y. Rhee, Gregory T. Robertson, Jeremy Michael Rock, Eric J. Rubin, Betsy Russell, David G. Russell, James C. Sacchettini, Dirk Schnappinger, Michael Schrimpf, Anna M. Upton, Peter Warner, Paul Graham Wyatt, Ying Yuan

Research output: Contribution to journalComment/debatepeer-review

Abstract

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.
Original languageEnglish
Pages (from-to)1333-1337
Number of pages5
JournalNature Medicine
Volume27
Early online date5 Jul 2021
DOIs
Publication statusPublished - Aug 2021

Keywords

  • Bacterial infection
  • Drug development
  • Drug screening
  • Intellectual-property rights
  • Research management

Fingerprint

Dive into the research topics of 'The Tuberculosis Drug Accelerator at year 10: what have we learned?'. Together they form a unique fingerprint.

Cite this